After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

The mRNA molecule eventually breaks down in the body. The Cleveland Clinic reports that the risks of mRNA vaccines include ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

A featured story from Pfizer explains that it has been making flu vaccines for 70 years, but the mRNA technology promises a major advance. The partnership with BioNTech is working on this now.

Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...